Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma

LONDON, September 26, 2014 /PRNewswire/ --

The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Incyte Corp.'s stock fell 1.36%, to close the day at $48.66. The stock recorded a trading volume of 0.87 million shares, below its three months average volume of 0.97 million shares. The company's shares oscillated between $48.13 and $49.88 during the session. Over the last one month and over the past three months, Incyte Corp.'s shares have lost 8.88% and 13.45%, respectively. However, the stock has gained 2.64% in the previous three trading sessions. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $54.02 is above its 50-day moving average of $49.68. Additionally, the stock has a Relative Strength Index (RSI) of 47.38. Sign up and read the free notes on INCY at:

http://www.Investor-Edge.com/INCY-26Sep2014

On Thursday, shares in Regado Biosciences Inc. recorded a trading volume of 1.87 million shares, higher than its three months average volume of 0.87 million shares. The stock ended the day at $1.18, which was 15.69% above its previous day's closing of $1.02, and registered an intraday range of $1.01 and $1.20. Although Regado Biosciences Inc.'s stock has gained 19.43% in the previous three trading sessions and 4.42% in the last one month, it has plummeted 75.26% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $2.02 and $5.60, respectively. Furthermore, shares of the company have an RSI of 24.28. On September 24, 2014, Regado Biosciences Inc. announced a reduction of its workforce by approximately 60%, or 20 employees, across all operational sites. The company expects that the reduction in workforce, coupled with the termination of expenses associated with its REGULATE-PCI clinical trial, will significantly decrease annualized cash expenditures. The complimentary notes on RGDO can be downloaded as in PDF format at:

http://www.Investor-Edge.com/RGDO-26Sep2014

ACADIA Pharmaceuticals Inc.'s stock declined 4.17% to end Thursday's session at $25.71. The stock recorded a trading volume of 1.29 million shares, above its three months average volume of 1.18 million shares. The company's shares fluctuated between $25.56 and $26.99 during the session. ACADIA Pharmaceuticals Inc.'s shares have advanced 2.88% since the beginning of 2014. Further, the stock has gained 11.06% in the last one month and 11.59% over the previous three months. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $23.42 is above its 200-day moving average of $23.19. Additionally, the stock has an RSI of 58.35. Register for free on Investor-Edge and access the latest research on ACAD at:

http://www.Investor-Edge.com/ACAD-26Sep2014

On Thursday, shares in Pharmacyclics Inc. fluctuated between $116.55 and $119.61 before ending the session 1.42% lower at $117.47. The stock reported a trading volume of 0.65 million shares, lower than its three months average volume of 0.98 million shares. Shares of the company traded at a PE ratio of 105.83. Pharmacyclics Inc.'s shares have fallen by 2.06% in the previous three trading sessions, while the stock has gained 32.87% in the last three months, and 11.05% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $117.37 and $111.89, respectively. Moreover, shares of Pharmacyclics Inc. have an RSI of 47.67. The complete research on PCYC is available for free at:

http://www.Investor-Edge.com/PCYC-26Sep2014

Raptor Pharmaceutical Corp.'s stock finished Thursday's session 3.06% lower at $10.15. A total of 0.28 million shares were traded, which was much below its three months average volume of 0.65 million shares. The stock vacillated between $10.11 and $10.65 during the session. Over the last one month and over the previous three months, Raptor Pharmaceutical Corp.'s shares have lost 10.89% and 8.89%, respectively. Additionally, from the beginning of 2014, the stock has declined 22.04%. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $11.42 is greater than its 50-day moving average of $10.11. Raptor Pharmaceutical Corp.'s stock has an RSI of 47.90. Free in depth research on RPTP is available at:

http://www.Investor-Edge.com/RPTP-26Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED